Bengaluru: Samsung Medison has completed the acquisition of Sonio SAS. Closing of the transaction I was subject to Applicable regulatory approvalsin particular the approval of the French Ministry of Economy and Finance. Following completion of the transaction, Sonio will remain an independent company based in France and will continue its commercial growth independently.
Sonio was established in 2020 with the mission of improving the situation of women and Child health worldwideThe company developed industry-leading IT solutions and AI assistance features for OB/GYN ultrasound that strongly assisted medical professionals in evaluating and documenting ultrasound examinations.
Sonio Detect, an FDA 510(k) cleared artificial intelligence assistant, provides accurate feedback on ultrasound examination quality and demonstrates remarkable performance with sensitivity over 90 percent in Fetal ultrasound recognition Together with Sonio’s AI expertise, Samsung Medison ultrasound systems will help bring innovative AI-enhanced workflows to market and accelerate innovation in patient outcomes and quality of prenatal care.
Deepak Prakash, Chief Technology Officer, Sonio SAS, said: “Together, Samsung and Sonio aim to bring about a transformative change in prenatal ultrasound exams “This would be especially a game changer in developing regions of the world, including India,”
Yong Kwan Kim, CEO of Samsung Medison, said: “The collaboration with Sonio will bring together the best in class.” Ultrasound artificial intelligence technology and reporting capabilities.”
Cécile Brosset, CEO and co-founder of Sonio, said: “In addition to the close collaboration with Samsung Medison, as an independent company, Sonio will continue to move forward Medical Reporting Technology and diagnostic software globally, including for underserved areas of healthcare.”
